Related Experiment Video
Updated: Jul 8, 2026

06:21
Assessment of the Metabolic Profile of Primary Leukemia Cells
Published on: November 21, 2018
Laboratory tumor lysis syndrome complicating LBH589 therapy in a patient with acute myeloid leukaemia
1Department of Clinical Haematology and Bone Marrow Transplantation, The Alfred Hospital, Melbourne, Australia.
Haematologica
|January 2, 2008
Abstract:
LBH589 is a novel cinnamic hydroxamic acid analog (HAA) pan-histone deacetylase inhibitor (HDACi) currently in early phase clinical development.
